FRT
55
7
AMGN
21
-2
GPC
50
3
FIS
75
2
GD
63
11
FLR
48
3
DE
55
-5
HD
50
3
CCL
53
6
BAX
48
-2
EQIX
55
2
F
54
2
AMP
57
3
AON
69
-6
FITB
59
4
APH
67
5
AMT
52
-4
EW
36
2
FOXA
67
3
GLW
44
3
FRT
55
7
AMGN
21
-2
GPC
50
3
FIS
75
2
GD
63
11
FLR
48
3
DE
55
-5
HD
50
3
CCL
53
6
BAX
48
-2
EQIX
55
2
F
54
2
AMP
57
3
AON
69
-6
FITB
59
4
APH
67
5
AMT
52
-4
EW
36
2
FOXA
67
3
GLW
44
3
Financhill
Back

BioXcel Therapeutics 10K Form

Sell
19

BTAI
BioXcel Therapeutics

Last Price:
$1.97
Seasonality Move:
7.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BTAI News And Ratings

See the #1 stock for the next 7 days that we like better than BTAI

BTAI Financial Statistics

Sales & Book Value

Annual Sales: $2.3M
Cash Flow: $-16.3M
Price / Cash Flow: 0
Annual Sales: $-2.02
Price / Book: 0

Profitability

EPS (TTM): -2.16000
Net Income (TTM): $-71M
Gross Margin: $123K
Return on Equity: 0%
Return on Assets: -95.73%

BioXcel Therapeutics Earnings Forecast

Key BioXcel Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for BTAI is 5.43%.
  • The Selling, General & Administrative Expenses for BTAI have been equal to 1,522.15% of Gross Profit Margin.
  • The Research & Development expenses have been 1,343.12% of Revenue.
  • The Net Earning history of BTAI is -2,630.14% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

BioXcel Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BTAI
CUSIP: 09075P
Website: bioxceltherapeutics.com

Debt

Debt-to-Equity Ratio: -1.22
Current Ratio: 1.87
Quick Ratio: 1.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BTAI Technical Analysis vs Fundamental Analysis

Sell
19
BioXcel Therapeutics (BTAI) is a Sell

Is BioXcel Therapeutics a Buy or a Sell?